Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT OTCMKTS:EMIS NASDAQ:KDNY NASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/AVERUVeru$0.60+0.7%$0.57$0.45▼$1.42$88.61M-0.752.91 million shs808,827 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+1.27%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%KDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%VERUVeru0.00%+0.08%-1.73%+10.10%-36.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVERUVeru2.8898 of 5 stars3.54.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AEMISEmisphere Technologies 0.00N/AN/AN/AKDNYChinook Therapeutics 0.00N/AN/AN/AVERUVeru 3.00Buy$4.00561.70% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AKDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85VERUVeru$16.89M5.25N/AN/A$0.22 per share2.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AKDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/AVERUVeru-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)Latest KDNY, EMIS, CALT, and VERU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q2 2025VERUVeru-$0.06-$0.05+$0.01-$0.05$0.73 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59EMISEmisphere TechnologiesN/AN/AN/AKDNYChinook TherapeuticsN/A5.825.82VERUVeruN/A3.803.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%EMISEmisphere TechnologiesN/AKDNYChinook Therapeutics95.15%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%EMISEmisphere Technologies72.90%KDNYChinook Therapeutics16.79%VERUVeru15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableVERUVeru230146.58 million124.30 millionOptionableKDNY, EMIS, CALT, and VERU HeadlinesRecent News About These CompaniesVeru And Two Other Penny Stocks To ConsiderJune 26, 2025 | finance.yahoo.comVeru Inc (FMW.DU)June 26, 2025 | nz.finance.yahoo.comVeru reports positive results for enobosarm in weight management studyJune 26, 2025 | uk.investing.comWhy Veru Inc. Is Rising In Pre-market? - NasdaqJune 26, 2025 | nasdaq.comVeru (NASDAQ:VERU) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedJune 25, 2025 | marketbeat.comOne Veru Insider Raised Stake By 150% In Previous YearJune 22, 2025 | finance.yahoo.comScholar Rock drug preserves muscle in obesity trialJune 18, 2025 | yahoo.comTraders Buy High Volume of Put Options on Veru (NASDAQ:VERU)June 17, 2025 | marketbeat.comVeru (NASDAQ:VERU) Stock Crosses Below 200-Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comVeru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025June 11, 2025 | quiverquant.comQVeru to Participate in the Virtual BTIG Obesity Health ForumJune 11, 2025 | globenewswire.comBeyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leaveMay 30, 2025 | seekingalpha.comVeru’s obesity drug roughly as safe as Wegovy; Keros’ board fightMay 28, 2025 | endpts.comEMuscle-sparing obesity drug safe for Phase 3 trial, Veru saysMay 28, 2025 | yahoo.comVeru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with SemaglutideMay 28, 2025 | quiverquant.comQVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneMay 28, 2025 | globenewswire.comVeru: Saving Muscle Mass Amidst The GLP-1 Drug BoomMay 26, 2025 | seekingalpha.comYoungsters at Dunstable school hear about the dangers of knife crimeMay 22, 2025 | msn.comVeru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressMay 8, 2025 | finanznachrichten.deVeru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trialMay 8, 2025 | msn.comVeru Inc. (VERU) Q2 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKDNY, EMIS, CALT, and VERU Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/11/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Emisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Chinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Veru NASDAQ:VERU$0.60 +0.00 (+0.67%) Closing price 04:00 PM EasternExtended Trading$0.60 0.00 (-0.08%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
